Biotechnology firm Enveric Biosciences (NASDAQ:ENVB) revealed additional preclinical findings reinforcing the non-hallucinogenic nature of its primary drug candidate, EB-003. The company aims to treat psychiatric and neurological disorders by preserving…
Read More
In this Q&A, Tucker explains what set Enveric apart from the first wave of psychedelic biotech companies: rather than rushing traditional molecules into the clinic, the team chose to do…
Read More
As clinical research advances beyond first-generation compounds, scientists are rethinking what psychedelic-inspired therapies could look like and how they may reshape the future of mental healthcare. Full Article >>
Read More
OpenAI CEO Sam Altman, once a “very anxious, unhappy person,” credits a psychedelic experience at a weekend-long retreat with helping him become a new man. He’s not unique among Silicon…
Read More
U.S. President Donald Trump's executive order to accelerate psychedelic drug development has raised hopes among companies developing the drugs that it could help attract more capital, but researchers cautioned that…
Read More
Depression is thought to affect approximately 5% of adults worldwide. It encompasses several different depressive disorders, including major depressive disorder, seasonal affective disorder, and persistent depressive disorder, all of which…
Read More
The White House recently issued an executive order accelerating the use of psychedelics, such as psilocybin, MDMA, and ibogaine, in research and clinical trials. This order, however, does not change…
Read More
For an industry built on the promise of transformation, psychedelic medicine is starting to look a lot more like traditional pharma. The language has shifted. Words like “set and setting”…
Read More
Enveric Biosciences Inc. (NASDAQ:ENVB) on Tuesday highlighted preclinical findings for its lead candidate EB-003. It pointed to rapid reductions in PTSD-related fear responses, as recent federal policy signals growing support…
Read More
The psychedelic medicine sector has spent years building momentum on the back of compelling clinical narratives. But as 2026 unfolds, the conversation is evolving into something more technical, and arguably…
Read More
